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Nebulised antibiotics are associated with increased Aspergillus colonisation. It is not
known whether this effect leads to increased Aspergillus antibodies or more frequent
use of anti-fungal medication. Recent in-vitro data also suggests that colomycin may
have fungicidal properties.
We reviewed 129 adult patients classiﬁed as chronically colonised with Pseudomonas.
Patients were receiving either long-term nebulised colomycin, nebulised tobramycin, or
no antibiotic (Table 1). Patients not receiving nebulised antibiotics had lower Aspergillus
positivity in sputum (p = 0.003) and lower speciﬁc Aspergillus IgE levels (p = 0.001).
There was a trend to lower total IgE and use of anti-fungal medication. No signiﬁcant
differences were seen between the colomycin and tobramycin groups aside from the
colomycin group received less anti-fungal medication (p = 0.03).
Table 1. Effects of nebulised antibiotics
Tobramycin
(n = 30)
Colomycin
(n = 76)
No antibiotic
(n = 23)
Age 29 (20−44) 30 (18−69) 28 (18−42)
Predicted FEV1 (%) 60 (30−96) 58 (8–127) 61 (24−99)
Total IgE (ku/l) 243 (4–1213) 168 (0–1614) 109 (6–773)
Speciﬁc IgE to Aspergillus (kua/l) 8.30 (0−56) 4.71 (0–62.6) 1.47 (0–5.35)*
Aspergillus IgG (mgA/l) 77.5 (15.7–200) 83.8 (6.6–201) 71.6 (2.7–201)
Use of antifungal in previous
12 months
63%* 39% 39%
Percentage sputum positivity for
Aspergillus
8.4% 13.7% 5.9%*
This data supports the ﬁnding of increased colonisation in patients on nebulised
antibiotics. We also observed increased Aspergillus antibodies in this group. These
effects are likely due to the counterbalance between Pseudomonas and Aspergillus, by
reducing Pseudomonas load Aspergillus can proliferate. Contamination of nebuliser
systems with Aspergillus is reported to be uncommon. Whether colomycin confers any
advantage is unclear.
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Objective: To evaluate current CF microbiology practice in UK laboratories.
Methods: Invitations were sent out to 81 microbiology laboratories providing
support to CF Centres/Clinics in the UK to participate in an on-line survey.
Participants answered questions on methods for processing CF respiratory samples,
including homogenisation, microscopy, culture, identiﬁcation, susceptibility testing,
use of reference laboratories, and communication of results to CF clinicians.
Results: 35 (43%) laboratories participated. Only 45% diluted sputum whilst
91% reported the number of micro-organisms present (mostly semi-quantitation).
Although 97% of laboratories used selective media to isolate Burkholderia cepacia
complex (Bcc), only 77%, 66% and 34% used selective media for fungi, S. aureus
and P. aeruginosa, respectively. Most used molecular methods to conﬁrm identity
of Bcc and other CF-associated pathogens; only three used in-house methods, but
most used the national reference laboratory. Of concern, four laboratories (12%)
did not use molecular identiﬁcation methods. Disc diffusion was the most common
susceptibility testing method (89% of laboratories), but there was considerable
variability in how colonies were selected for testing. Microbiologists in 11 centres
(31%) attended multi-disciplinary team meetings, but in six of these it was only
four times a year or less.
Conclusion: A wide variability in practice was observed in UK microbiology
laboratories when processing CF respiratory samples. In September 2010 the UK CF
Trust published evidence-based guidelines for microbiology laboratories processing
CF respiratory samples. A future audit is planned to assess their impact.
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Introduction: The Cystic Fibrosis (CF) lung presents a complex polymicrobial
ecology. One of the most commonly associated pathogens is Pseudomonas aerug-
inosa. This pathogen is capable of sustaining a chronic infection via formation of
multicellular structures known as bioﬁlms, making infection extremely difﬁcult to
treat with conventional antibiotic therapy. Routine antibiotic susceptibility testing
of strains relies on the testing of a single ‘morphotype’ planktonically.
Methods: We tested 44 morphotypically identical P. aeruginosa colonies taken from
a single sputum sample. Our aim was to test whether phenotypic and antibiotic
susceptibility proﬁles differ between identical morphotypes, if so, does testing a
single colony provide accurate information for the clinician? Phenotypic assays
were performed including growth and pyocyanin production. Using the ‘Peg Bioﬁlm
Assay’ colonies were tested for susceptibility to common CF therapeutics in the
planktonic and bioﬁlm modes of growth, both singly and in combination in order
to compare susceptibility proﬁles of these combinations with the regularly used
laboratory method.
Results: Initial phenotypic analysis has demonstrated large variances in both
population growth and pyocyanin production between colonies, despite all being
morphologically identical. We will report our ﬁndings on bioﬁlm formation and
antibiotic susceptibilities.
Discussion: We demonstrate that morphologically identical colonies can display
huge phenotypic differences, which suggests that analysing several colonies of
the same morphotype will provide a more accurate method for determining the
antibiotic sensitivity of P. aeruginosa in the CF lung.
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Introduction: An audit of the microbiology results of patients attending the CF
clinic at a Tertiary Hospital in UK over 1 year period was conducted in 2005 and
microbiology results were reviewed using the Hospital web system. The information
with regards to the type of sample taken, organisms cultured, sensitivities of
organisms to antibiotics, typing of Pseudomonas and macroscopic appearance of
these specimens was audited. The study highlighted important facts in the reporting
like only 1 specimen of the 44 Pseudomonas was reported as being mucoid with no
comments on the others. Only 14% Pseudomonas were reported as aeruginosa and
86% reported as species. The Pseudomonas routinely had only 6 drugs tested for
sensitivity omitting important drugs like colistin. There was recommended practice
change suggested after a MDT with Microbiologist and the CF team and a repeat
audit of the same was done in 2010 over a 1 year period on a similar population
attending CF clinic.
The audit in 2010 showed improvement in the practice with a increase in the
Pseudomonas species being typed increasing to 86%. There was a 95% antibiotic
sensitivity testing to 12 antibiotics commonly used in CF patients. There was still
poor reporting of the Pseudomonas aeruginosa as mucoid or not. Though all
patients coming to CF clinic are screened for cepacia there was only 3 positive
results.
Conclusion: It is a good practice to re-evaluate the current practice, the audit
in 2005 helped us to understand the ﬂaws in reporting and was highlighted to the
microbiologist and a change in practice noted. It improved our clinical management
but there is still a long way to go to perfection but it is a start.
